¹Ì±¹ÀÇ Àü¸³¼±¾Ï ÇÙÀÇÇÐ Áø´Ü ½ÃÀå ±Ô¸ð, Á¡À¯À² ¹× µ¿Ç⠺м® º¸°í¼­ : Á¦Ç° À¯Çüº°, PET Á¦Ç°º°, ºÎ¹®º° ¿¹Ãø(2023-2030³â)
U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Size, Share & Trends Analysis Report By Type (SPECT, PET), By PET Product (F-18, SR-82/RB-82), And Segment Forecasts, 2023 - 2030
»óǰÄÚµå : 1405747
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2023³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 80 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,609,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,950 £Ü 10,055,000
Printable PDF (5-User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,949,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¹Ì±¹ÀÇ Àü¸³¼±¾Ï ÇÙÀÇÇÐ Áø´Ü ½ÃÀå ¼ºÀå ¹× µ¿Çâ :

Grand View ResearchÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¹Ì±¹ÀÇ Àü¸³¼±¾Ï ÇÙÀÇÇÐ Áø´Ü ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 1¾ï 5,397¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

2023³âºÎÅÍ 2030³â±îÁö CAGRÀº 9.2%·Î ¿¹ÃøµË´Ï´Ù. ¹Ì±¹¾ÏÇùȸ(ACS)¿¡ µû¸£¸é 2019³â ¹Ì±¹¿¡¼­´Â 174,650¸íÀÇ ½Å±Ô ȯÀÚ ¹× 31,620¸íÀÇ Àü¸³¼±¾Ï »ç¸ÁÀÚ°¡ ¹ß»ýÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Ç¥Àû ÁúȯÀÇ °ËÃâÀ» °³¼±Çϱâ À§ÇÑ »õ·Î¿î ¹æ»ç¼ºÀǾàǰ ½ÃÀå °³Ã´Àº ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈ­ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, Àü¸³¼± ƯÀÌÀû ¸· Ç׿ø(PSMA)À» Ç¥ÀûÀ¸·Î ÇÏ´Â »õ·Î¿î À̹Ì¡ ¾à¹°ÀÌ 68Ga¿Í 18F ¹æ»ç¼º µ¿À§¿ø¼Ò¸¦ »ç¿ëÇÏ¿© °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾çÀüÀÚ¹æÃâ´ÜÃþÃÔ¿µ(PET)À» À§ÇÑ »õ·Î¿î Áø´Ü ¾à¹°À» °³¹ßÇϱâ À§ÇØ ¿¬±¸ÀÚµéÀº ±âÁ¸ ¾à¹°¿¡ ºñÇØ ´õ ³ôÀº È¿À²À» °¡Áø »õ·Î¿î Áø´Ü ¾à¹°À» °³¹ßÇϱâ À§ÇØ ¸¹Àº ¿¬±¸¸¦ ÁøÇàÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 89Zr-huJ591Àº Àü¸³¼±¾ÏÀ» °ËÃâÇϱâ À§ÇØ PET¿¡ »ç¿ëµÇ´Â À̹Ì¡ ¾à¹°ÀÔ´Ï´Ù. ÀÌ ¾à¹°Àº ÀÓ»ó I/II ´Ü°è¿¡ ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ ³»¿¡ Ãâ½ÃµÉ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

Á¤È®ÇÑ Áø´Ü ¹æ¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ¹Ì±¹ÀÇ Àü¸³¼±¾Ï ÇÙÀÇÇÐ Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, PET´Â ÀϹÝÀûÀ¸·Î ¾Ç¼º Á¾¾çÀÇ Áø´Ü Á¤È®µµ¸¦ ³ôÀ̱â À§ÇØ MRI ¹× CT ½ºÄµ°ú ÅëÇյǴ °ÍÀÌ ÀϹÝÀûÀÔ´Ï´Ù. µû¶ó¼­ ¿¬±¸ÀÚµéÀº ȯÀÚÀÇ °á°ú¸¦ °³¼±Çϱâ À§ÇØ PET/MRI¿¡ ´ëÇÑ ¿¬±¸¸¦ ÁøÇàÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2018³â 12¿ù The Journal of Nuclear Medicine¿¡ 68Ga-PSMA-11 PET/MRI°¡ Ç¥Àû Á¾¾ç °ËÃâ¿¡ À¯¸®ÇÏ´Ù´Â ¿¬±¸ °á°ú°¡ ¹ßÇ¥µÇ¾ú½À´Ï´Ù.

´Ù¾çÇÑ ºñ¿µ¸® ´Üü°¡ Á¾¾ç Áø´ÜÀ» À§ÇÑ »õ·Î¿î ¿µ»ó Áø´Ü ¾àǰÀÇ µµÀÔ¿¡ µµ¿òÀÌ µÇ´Â Á¶»ç ¿¬±¸¿¡ ÀÚ±ÝÀ» Áö¿øÇϰí ÀÖÀ¸¸ç, The Prostate Cancer FoundationÀº 20³â ÀÌ»ó PSMA-PET ¿µ»ó °³¹ßÀ» À§ÇÑ ´Ù¾çÇÑ ¿¬±¸¿¡ ÀÚ±ÝÀ» Áö¿øÇØ ¿Â ÁÖ¿ä ´Üü Áß ÇϳªÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÀÚ±Ý Áö¿ø ´Üü ¹× ÇÁ·Î±×·¥ÀÇ Á¸Àç´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÁÖ¿ä ½ÃÀå ±â¾÷µéÀº ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­Çϱâ À§ÇØ Àü·«Àû ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2018³â 2¿ù Axumin(fluciclovir F 18) ÁÖ»çÁ¦´Â Àü¸³¼±¾Ï Á¾¾çÇп¡ ´ëÇÑ NCCN(National Comprehensive Cancer Network)ÀÇ ÀÓ»ó Áø·á Áöħ¿¡ Ãß°¡µÆ½À´Ï´Ù. ÀÓ»óÀÇ¿Í ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü°¡ »ç¿ëÇÏ´Â ¾÷µ¥ÀÌÆ®µÈ °¡À̵å¶óÀο¡´Â Àç¹ß ¶Ç´Â ÁøÇ༺ Àü¸³¼±¾Ï ȯÀÚÀÇ ÀÓ»ó °Ë»ç¿¡¼­ PET/MRI ¶Ç´Â PET/CT¸¦ À§ÇÑ Ç÷ç½ÃŬ·Îºó F 18 Áֻ簡 °í·ÁµÉ ¼ö ÀÖ´Ù°í ¸í½ÃµÇ¾î ÀÖ½À´Ï´Ù.

¹Ì±¹ÀÇ Àü¸³¼±¾Ï ÇÙÀÇÇÐ Áø´Ü ½ÃÀå º¸°í¼­ÀÇ ÁÖ¿ä ³»¿ë :

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¹Ì±¹ÀÇ Àü¸³¼±¾Ï ÇÙÀÇÇÐ Áø´Ü ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå ¹Ì±¹ÀÇ Àü¸³¼±¾Ï ÇÙÀÇÇÐ Áø´Ü ½ÃÀå : À¯Çü ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå ¹Ì±¹ÀÇ Àü¸³¼±¾Ï ÇÙÀÇÇÐ Áø´Ü ½ÃÀå : PET Á¦Ç° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå °æÀï ±¸µµ

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Growth & Trends:

The U.S. prostate cancer nuclear medicine diagnostics market size is expected to reach USD 153.97 million by 2030, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 9.2% from 2023 to 2030. According to the American Cancer Society (ACS), in 2019, 174,650 new cases and 31,620 deaths caused by caused by prostate cancer are expected to be recorded in U.S. Such high prevalence of the disease is expected to drive the market growth.

Development of novel radiopharmaceuticals to improve the detection of the target disease is anticipated to accelerate the market growth. For instance, new imaging agents targeting Prostate-specific Membrane Antigen (PSMA) are being developed using 68Ga and 18F radioisotopes. In addition, numerous studies are being performed by researchers to develop new diagnostic agents for Positron Emission Tomography (PET) with higher efficiency as compared to the existing agents. For instance, 89Zr-huJ591 is an imaging agent used with PET for the detection of prostate cancer. This agent is in phase I/II of clinical trials, and is likely to get launched over the forecast period.

Growing demand for accurate diagnostic methods is estimated to fuel growth of the U.S. prostate cancer nuclear medicine diagnostics market. PET is commonly integrated with MRI and CT scan to enhance accuracy of diagnosis in malignancies. Therefore, researchers are conducting studies on PET/MRI to improve patient outcomes. For instance, in December 2018, a study was published in The Journal of Nuclear Medicine stating that 68Ga-PSMA-11 PET/MRI can be advantageous in detecting the target tumor.

Various non-profit organizations fund research studies to help introduce new imaging agents for the diagnosis of tumors. The Prostate Cancer Foundation is one of the major organizations that has been funding different studies for the development of PSMA-PET imaging for over 20 years. Presence of such funding organizations and programs is expected to boost the market growth during the forecast period.

Key market players have undertaken strategic initiatives to strengthen their market presence. For instance, in February 2018, Axumin (fluciclovine F 18) injection was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Prostate Cancer. The updated guidelines used by clinicians and healthcare providers stated that fluciclovine F 18 for PET/MRI or PET/CT is considered in the clinical workup of patients with recurrent or advanced prostate cancer.

U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Variables, Trends & Scope

Chapter 4. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: Type Estimates & Trend Analysis

Chapter 5. U.S. Prostate Cancer Nuclear Medicine Diagnostics Market: PET Product Estimates & Trend Analysis

Chapter 6. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â